VAC85135 + Ipilimumab
Phase 1Completed 0 watching 0 views this week💤 Quiet
32
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Myeloproliferative Neoplasms
Conditions
Myeloproliferative Neoplasms
Trial Timeline
Jul 21, 2022 → Jun 24, 2025
NCT ID
NCT05444530About VAC85135 + Ipilimumab
VAC85135 + Ipilimumab is a phase 1 stage product being developed by Bristol Myers Squibb for Myeloproliferative Neoplasms. The current trial status is completed. This product is registered under clinical trial identifier NCT05444530. Target conditions include Myeloproliferative Neoplasms.
Hype Score Breakdown
Clinical
10
Activity
5
Company
9
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05444530 | Phase 1 | Completed |
Competing Products
20 competing products in Myeloproliferative Neoplasms
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| LY2784544 | Eli Lilly | Phase 1 | 33 |
| LY2784544 | Eli Lilly | Phase 1 | 33 |
| Navitoclax + Ruxolitinib + Celecoxib | AbbVie | Phase 1 | 33 |
| AUY922 | Novartis | Phase 2 | 52 |
| Pacritinib + Decitabine + Decitabine and Cedazuridine + Azacitidine | Swedish Orphan Biovitrum | Phase 2 | 51 |
| Fedratinib Pill | Bristol Myers Squibb | Phase 2 | 51 |
| Fedratinib Pill | Bristol Myers Squibb | Phase 1 | 32 |
| Fedratinib Oral Capsule 300 mg + Decitabine 20 mg/m2 + Fedratinib Oral Capsule 400 mg | Bristol Myers Squibb | Phase 1 | 32 |
| Ruxolitinib | Incyte | Phase 2 | 49 |
| Parsaclisib + Parsaclisib + Ruxolitinib + Parsaclisib + Parsaclisib | Incyte | Phase 2 | 49 |
| INCA036978 + Standard disease-directed therapy | Incyte | Phase 1 | 30 |
| Ruxolitinib | Incyte | Phase 2 | 49 |
| Ruxolitinib + Anagrelide + Placebo + Placebo | Incyte | Phase 2 | 49 |
| Ruxolitinib + Lenalidomide + Prednisone | Incyte | Phase 2 | 49 |
| itacitinib | Incyte | Phase 2 | 49 |
| Ruxolitinib + Placebo | Incyte | Phase 3 | 74 |
| INCB160058 + Standard disease-directed therapy | Incyte | Phase 1 | 30 |
| Pemigatinib | Incyte | Phase 2 | 49 |
| Itacitinib + Ruxolitinib | Incyte | Phase 2 | 49 |
| INCA035784 | Incyte | Phase 1 | 30 |